The Cyrex Labs Array 20 is a blood test that is used to detect blood-brain-barrier permeability. Its clinical uses include early investigation in management of contact sports-related Traumatic Brain Injury (TBI/Concussion). The Blood Brain Barrier Permeability Test along with Array 7 can also be used to assess the increased risk of neurodegenerative diseases, including but not limited to Multiple Sclerosis, Lou Gehrig’s Disease (ALS), Senile Dementia, Alzheimer’s, Parkinson’s, Epilepsy, and Stroke.
“Brain injuries, prevalent in contact sports, falls, accidents or other activities that involve shock to the head, make Array 20 essential for head injury evaluation,” said Dr. Aristo Vojdani, developer of the Blood Brain Barrier Permeability Test, pioneer of ELISA clinical testing and Chief Scientific Advisor of Cyrex Labs.
When the blood-brain-barrier has been damaged through injuries such as a concussion, killer proteins are permitted entry into the brain. Once this occurs, antibodies such as IgG, IgA, and IgM are produced against those killer proteins. When these antibodies are left untreated, they may become destructive to brain tissue, which leads to neurodegenerative diseases, like ALS. The Array 20 combined with the Array 7 can detect these specific antibodies, and can therefore assist physicians in early TBI treatment to reduce risk of neurodegeneration.
It is important to note that when the antibodies IgG, IgA, and IgM are present in an Array 20 test, they indicate that the blood-brain-barrier is disrupted. What does this mean? Until the blood-brain-barrier has been healed from a concussion, the athlete is susceptible to Second-Impact-Syndrome, which has proven fatal. If you return to contact before allowing the blood-brain-barrier time to heal completely, the next concussion can create an irreversible autoimmune reaction. This may lead to neurodegeneration. For these reasons, complete blood-brain-barrier healing is vital to preventing Second-Impact-Syndrome.